Dr. Rustgi has assembled the leading experts in the management of Heptatitis B to present the current treatment and clinical course for diagnosis and management of the disease. Articles are devoted to: Drug metabolism in the liver; Mechanism of Liver Damage including the RUCAM scale; Drug-induced acute liver failure; Epidemiology and genetic risk factors; Adverse drug reactions: type A (intrinsic or pharmacological) or type B (idiosyncratic); Pathology of injury including phenotypes; The clinical course of drug-induced liver disease; Environmental factors of drug hepatotoxicity; Newer agents in drug hepatotoxicity; Drug hepatotoxicity: herbal products; Drug hepatotoxicity: models including "human on a chip" and zebrafish; Acute and chronic liver failure from drugs: impact on the kidney; and Management of acute hepatotoxicity including medical agents and liver support systems. Readers will come away with the cutting edge science behind the latest innovations in the treatment of Hepatitis B.

Dr. Levy has secured the field's top experts to offer the latest clinical reviews on cholestatic liver disease. The issue will include articles devoted to The Gut-Liver Axis; Update on Genetics in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis; New thoughts on IgG4 Associated Cholangitis; Cancer Risk and Surveillance in PSC; Novel Therapies for PBC; and Liver transplantation for Cholestatic Liver Diseases, to name a few. Dr. Levy's issue will be the most current authority on cholestatic liver disease.

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more.

Liver Pathophysiology: Therapies and Antioxidants is a complete volume on morphology, physiology, biochemistry, molecular biology and treatment of liver diseases. It uses an integral approach towards the role of free radicals in the pathogenesis of hepatic injury, and how their deleterious effects may be abrogated by the use of antioxidants. Written by the most prominent authors in the field, this book will be of use to basic and clinical scientists and clinicians working in the biological sciences, especially those dedicated to the study and treatment of liver pathologies.

In this issue of Clinics in Liver Disease, guest editor Dr. John V. Binu brings his considerable expertise to the topic of Primary Biliary Cholangitis. PBC leads to inflammation and scarring of the small bile ducts, and, if untreated, can lead to cirrhosis and liver failure. In this issue, top experts provide a state-of-the-art review of diagnosis and treatment for this chronic, progressive liver disorder. Contains 13 practice-oriented topics including genetics of primary biliary cholangitis; prognostic scoring systems in PBC; overlap syndromes and PBC; non-invasive evaluation of fibrosis and portal hypertension in PBC; treatment of PBC: first- and second-line therapies; novel therapies for PBC; and more. Provides in-depth clinical reviews on primary biliary cholangitis, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Radiologic Clinics, guest editors Drs. Benjamin M. Yeh and Frank H. Miller bring their considerable expertise to the topic of Hepatobiliary Imaging. Top experts in the field offer comprehensive reviews of every major aspect of hepatobiliary imaging: biliary cancer, trauma, vascular disorders, and benign liver disease. This issue also includes articles on imaging modalities (MR, CT, ultrasound), contrast agents, and "Pearls and Pitfalls." Contains 13 practice-oriented topics including abbreviated MR liver protocols; update on MR contrast agents for liver imaging: what to use and when; biliary imaging interpretation pearls and pitfalls: CT and MRI; update on biliary cancer imaging; atypical liver malignancies and diagnostic pitfalls; and more. Provides in-depth clinical reviews on hepatobiliary imaging, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Clinics in Liver Disease, guest editor Mitchell L Shiffman brings considerable expertise to the topic of Challenging Issues in the Management of Chronic Hepatitis B Virus. Provides in-depth, clinical reviews on the latest updates in Challenging Issues in the Management of Chronic Hepatitis B Virus, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

This field has shown tremendous growth in recent years, primarily due to the recognition that drug-induced liver disease is the most common cause of liver failure and one of the major contributors to the withdrawal of drugs developed by the pharmaceutical industry. Drug-Induced Liver Disease, 3rd edition is a comprehensive reference that covers mechanisms of injury, diagnosis and management, major hepatotoxins, regulatory perspectives and much more. Written by highly respected authorities, this new edition is an updated and definitive reference for clinicians and scientists in academia, the pharmaceutical industry and government settings. This book contains 4 new chapters on key topics in the area and provides a current and extensive review of the latest developments concerning the toxicology, pharmacology, genetics and immunology of drug-induced liver disease.

A multi-authored reference work written by leading clinical, academic and industry experts in drug-induced liver disease.

Contains four new chapters on key areas in the field, including one on worldwide drug-induced liver injury networks.

Each chapter has been updated to address the latest research and findings in the field and 16 new chapter authors have been added to this new edition.

Includes coverage of the basic, clinical and practical aspects of drug-induced liver disease to provide the single most comprehensive reference on the subject. "